Dupliyuzumab Injection is mainly used for the treatment of atopic dermatitis, but also for the treatment of asthma. Dupliyuzumab Injection belongs to a biological agent, the drug can selectively inhibit interleukins in the body, blocking the pathway of TH2-type inflammation, thus reducing the pathological response of TH2-type inflammation, mainly used for the treatment of adults with moderate and severe atopic dermatitis. Dupliyuzumab Injection is a targeted biologic approved for the treatment of moderate-to-severe atopic dermatitis in adults in China, providing a new treatment option for patients with moderate-to-severe atopic dermatitis. Duplizumab Injection can also be used to treat bronchial asthma, which can effectively reduce the number of asthma attacks and improve patients’ lung function after continuous use. The most common adverse reactions to this medication are injection site reactions, conjunctivitis, blepharitis, and oral herpes. It is contraindicated for those who have hypersensitivity reactions to the active ingredients of the drug or any other excipients. The drug should be applied strictly under medical supervision.